Real-world study of adverse events associated with ceftazidime/avibactam based on the U.S. Food and Drug Administration adverse event reporting system database

ObjectiveCeftazidime/avibactam (CZA), a combination of the third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase inhibitor avibactam, was widely used in the treatment of multidrug-resistant (MDR) Gram-negative bacterial pathogens. In light of the growing prevalence of MD...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Xin Zheng, Yang Peng, Yang-xue Ou, Bi-bo You, Lu Zhang, Yuan Cheng, Mo Cheng, Pu Xiang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-01-01
Edice:	Frontiers in Cellular and Infection Microbiology
Témata:	adverse events ceftazidime/avibactam combination FAERS respiratory failure safety signals
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fcimb.2026.1698293/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!